---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001294"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:20:53.197012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Charles River Q2 revenue up 8.9% to $1.06B; GAAP EPS $1.89, non-GAAP $2.69; guidance narrowed upward

## Summary
- Revenue $1.06B (+8.9% YoY, organic +11.2%); DSA segment revenue $663.5M (+12.1%) drove growth.
- GAAP net income $97.0M (−11.3%), diluted EPS $1.89; non-GAAP EPS $2.69 (−2.9%).
- RMS segment revenue $209.9M (+12.6%, organic +13.9%) driven by China model shipments; Manufacturing segment revenue $186.5M (−4.2%).
- FY 2023 guidance narrowed: organic revenue growth 5.5%–7.5% (prior 5.0%–7.5%); non-GAAP EPS $10.30–$10.90 (prior $9.90–$10.90).
- CEO cites cautious biopharma spending but confidence in differentiated scientific breadth and DSA backlog.

## SEC filing metadata
- accession: 0001157523-23-001294
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/0001157523-23-001294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/a53513759.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001294
- JSON: https://secwatch.observer/filing/0001157523-23-001294.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001294.txt

## Key facts
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the second quarter of 2023 results: revenue $1.06 billion, EPS $1.89. Guidance reaffirmed.
  - Period: the second quarter of 2023
  - Revenue: $1.06 billion
  - EPS: $1.89
  - Guidance: reaffirmed
  - Result: reported results
  source text: EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a53513759ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2023 Results – Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – WILMINGTON, Mass.--(BUSINESS WIRE)--August 9,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/0001157523-23-001294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.